Souhaitez-vous accéder aux communiqués récents ?

Nantes, France, 15 avril 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE), une société de biotechnologie au stade clinique développant des thérapies first-in-class en...

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meet

CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MDLifespan (www.mdlifespan.com), a physician-led public benefit corporation focused on reducing environmental toxin burden and chronic inflammation, today...

CHICAGO, IL, Dec. 23, 2025 (GLOBE NEWSWIRE) -- A treatment once reserved for scuba divers is gaining attention for its potential in treating a variety of ailments, including traumatic brain...

Pasithea’s PAS-004 shows superior ETS2 inhibition vs. selumetinib, highlighting promise as a new treatment for IBD and other inflammatory diseases.

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...

Chongqing, China, July 05, 2023 (GLOBE NEWSWIRE) -- Chongqing Joywin Natural Products Co., Ltd. (hereinafter referred to as Chongqing Joywin) is a company that focuses on extracting various natural...

GUILFORD, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development,...

VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc., a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...

VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...